Idifarma invests in automatic capsule filling capabilities
Idifarma’s facility in Pamplona, Spain.
Investment enables the CDMO to provide a one-stop-shop service from lab-scale development to manufacturing of clinical batches and dossier compilation to specialised commercial manufacturing.
Idifarma, a Spanish contract development and manufacturing organisation (CDMO) has expanded its GMP manufacturing offering with an investment in automatic capsule filling equipment.
Idifarma has acquired a Bosch GKF-702 capsule filling machine, capable of manufacturing 3,000-42,000 capsules per hour. The new equipment will be installed at the CDMO’s EU-GMP approved plant in Pamplona, Spain, in early 2017.
Commenting on the investment, Luis Oquiñena, general manager and co-founder of Idifarma says: “This is a significant milestone in our journey so far, helping us to become a leading CDMO for small-scale niche products in solid oral forms.
“Idifarma will continue to keep its contract manufacturing focus on specialised, low-volume pharmaceutical products where we can add real value to our clients’ projects involving innovative drugs and niche generics.
“This investment will also include the enlargement of our GMP plant with new rooms and capacity to handle high potency drugs, another clear differentiation and focus area for Idifarma.”
In addition to improving Idifarma’s contract manufacturing capabilities, the GKF-702 will also feature a 'lab kit', enabling the use of the machine during pharmaceutical development, resulting in a more efficient use of APIs and less wastage.
The new machine will benefit from other equipment that is already installed at Idifarma’s GMP plant including a Hüttlin Oyster high-shear mixer and dryer for wet granulation processes, bin blenders with capacity up to 70 kg and a Clinipack IMA blistering machine, with the ability to work with Alu/Alu or any thermo-formable material. Idifarma can also handle narcotics and low-humidity requirements.
Luis Oquiñena continued: “We are confident that this new investment will not only attract clients interested in production, but also contract development projects in hard capsule form in the coming months.
“Our customers can now benefit from a one-stop-shop service from lab-scale development to manufacturing of clinical batches and dossier compilation to specialised commercial manufacturing,” added Luis.
The investment in capsule filling equipment coincides with the 15th anniversary of Idifarma, which will grow its revenue in 2016 by over 25%. The team recently reached 100 people, with 50% of business now coming from outside of Spain.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.